Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors

Company Performance - Ginkgo Bioworks Holdings, Inc. (DNA) ended the latest trading session at $0.37, reflecting a +0.3% adjustment from the previous day's close, outperforming the S&P 500's daily loss of 0.5% [1] - The company's stock has increased by 12.72% over the past month, significantly surpassing the Medical sector's gain of 0.74% and the S&P 500's gain of 0.1% [6] Earnings Expectations - Analysts expect Ginkgo Bioworks to report earnings of -$0.08 per share in the upcoming earnings report, indicating a year-over-year growth of 11.11% [2] - For the entire fiscal year, Zacks Consensus Estimates predict earnings of -$0.30 per share and revenue of $175.18 million, reflecting changes of +23.08% and -30.33% from the previous year, respectively [7] Analyst Estimates - Recent changes to analyst estimates for Ginkgo Bioworks suggest a positive outlook, as these adjustments often reflect shifting short-term business dynamics [3] - The Zacks Rank system indicates that Ginkgo Bioworks currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining stagnant over the past month [10] Industry Context - Ginkgo Bioworks operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 81, placing it in the top 33% of over 250 industries [4]